Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,150.19 USD
+11.38 (1.00%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $1,150.20 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Regeneron Pharmaceuticals, Inc. [REGN]
Reports for Purchase
Showing records 141 - 160 ( 596 total )
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dupixent Scores Another Win, This One in Atopic Dermatitis - Reiterate Buy and Maintain PT of $787
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Phase 2 Top-line Results for High-Dose Eylea in Wet AMD Bolsters Bullish Outlook For Ongoing Phase 3 Studies
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
REGEN-COV Gains UK Conditional Marketing Approval; BLA Filed; Bullish Signs Abound for Prolonged Market Presence
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Regeneron Walks the Walk on Delivering Superb 2Q2021 Top and Bottom Line Performance
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Our Outlook for Regeneron?s Upcoming 2Q21 Earnings Report
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Expands Emergency Use Authorization for REGENCOV to Include Post-COVID Exposure
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
REGN Reports Positive Ph3 Results for Dupixent for Chronic Spontanous Urticaria; Reiterate Buy and Raising PT to $729.
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Regeneron and AstraZeneca Bet Big on Obesity and Forge a New Deal to Commercialize Novel Drugs for Novel Targets
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
REGEN-COV Can Neutralize the Delta Variant of COVID-19, Which is Rapidly Becoming the Dominant COVID-19 Strain Globally.
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Regeneron Genetics Center Strikes Again; Novel Target for Protection Against Obesity Identified
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and a 12-month price target of $703
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department